Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 on Thursday, April 26, 2018 at 08:00 a.m. CET.
BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on April 26, at 09:30 – 10:30 a.m. CET.
Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – March 2018 followed by a Q&A-session.
To attend, please dial-in at one of the numbers below from:
- Sweden: + 46 8 566 426 62
- Belgium: + 32 240 406 35
- Germany: + 49 692 222 290 46
- The Netherlands: + 31 207 168 416
- Norway: + 47 235 002 53
- Switzerland: + 41 225 675 548
- UK: + 44 203 008 9814
- US: + 1 855 831 5946
For more information, please contact:
Christina Astrén, IR & Communications Director
Telephone: + 46 70 835 43 36
BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com
This information was submitted for publication at 08:00 a.m. CET on April 12, 2018.